Multidisciplinary Essentials for Identifying and Optimally Treating Patients With Worsening Heart Failure
Tracking # 20-1314801
Free
Course overview
HF is a complex disease associated with adverse outcomes and poor quality of life for patients. It is also a significant driver of hospitalizations and readmissions. Delays in diagnosis, misdiagnosis, and undertreatment are common as patients often see a multitude of healthcare providers. Yet, early recognition and treatment are critical to reducing morbidity and mortality associated with HF, particularly those with worsening HF and after recent HF hospitalization. There have been significant advances in treatment with new disease-modifying agents introduced. Despite the accumulating evidence and calls for guideline-directed medical therapy, this approach is underutilized and clinicians struggle to initiate and optimize therapy in clinical practice. In addition, many clinicians remain unaware of novel strategies for patients with worsening HF or after recent HF hospitalization.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Stephen J. Greene, MD, FACC, FHFSA
Sources of Funding for Research: AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Otsuka, Pfizer, Sanofi
Consulting Agreements: AstraZeneca, Bayer, Bristol Myers Squib, Boehringer Ingelheim, Cytokinetics,
Corcept Therapeutics, CSL Vifor Cytokinetics, Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Sanofi Roche, Sumitomo, Tricog Health,
Stormi Gale, PharmD, BCCP, BCPS, FHFSA
Speakers' Bureau: American Regent